558 related articles for article (PubMed ID: 17890947)
1. A multiparameter test of clot formation and fibrinolysis for in-vitro drug screening.
Kostka B; Para J; Sikora J
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):611-8. PubMed ID: 17890947
[TBL] [Abstract][Full Text] [Related]
2. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
[TBL] [Abstract][Full Text] [Related]
3. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
[TBL] [Abstract][Full Text] [Related]
4. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
Guimarães AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
5. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
[TBL] [Abstract][Full Text] [Related]
6. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
von dem Borne PA; Cox LM; Bouma BN
Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
[TBL] [Abstract][Full Text] [Related]
7. Antithrombotic effects due to pharmacological modulation of thrombin-activatable fibrinolysis inhibitor in rats.
Soni H; Sharma A; Bhatt S; Jain MR; Patel PR
Pharmacology; 2008; 82(4):304-9. PubMed ID: 18936552
[TBL] [Abstract][Full Text] [Related]
8. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
[TBL] [Abstract][Full Text] [Related]
9. Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.
Liu JN; Liu JX; Liu Bf BF; Sun Z; Zuo JL; Zhang Px PX; Zhang J; Chen Yh YH; Gurewich V
Circ Res; 2002 Apr; 90(7):757-63. PubMed ID: 11964367
[TBL] [Abstract][Full Text] [Related]
10. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation.
Nielsen VG; Cohen BM; Cohen E
Blood Coagul Fibrinolysis; 2006 Jan; 17(1):75-81. PubMed ID: 16607085
[TBL] [Abstract][Full Text] [Related]
11. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
[TBL] [Abstract][Full Text] [Related]
12. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
[TBL] [Abstract][Full Text] [Related]
13. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis.
Lijnen HR; Stassen JM; Collen D
Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414
[TBL] [Abstract][Full Text] [Related]
14. Clot lysis time in platelet-rich plasma: method assessment, comparison with assays in platelet-free and platelet-poor plasmas, and response to tranexamic acid.
Panes O; Padilla O; Matus V; Sáez CG; Berkovits A; Pereira J; Mezzano D
Platelets; 2012; 23(1):36-44. PubMed ID: 21787173
[TBL] [Abstract][Full Text] [Related]
15. A new global assay of coagulation and fibrinolysis.
Goldenberg NA; Hathaway WE; Jacobson L; Manco-Johnson MJ
Thromb Res; 2005; 116(4):345-56. PubMed ID: 16038720
[TBL] [Abstract][Full Text] [Related]
16. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
17. Görög Thrombosis Test: a global in-vitro test of platelet function and thrombolysis.
Yamamoto J; Yamashita T; Ikarugi H; Taka T; Hashimoto M; Ishii H; Watanabe S; Kovacs IB
Blood Coagul Fibrinolysis; 2003 Jan; 14(1):31-9. PubMed ID: 12544726
[TBL] [Abstract][Full Text] [Related]
18. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
[TBL] [Abstract][Full Text] [Related]
19. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit.
Marder VJ; Landskroner K; Novokhatny V; Zimmerman TP; Kong M; Kanouse JJ; Jesmok G
Thromb Haemost; 2001 Sep; 86(3):739-45. PubMed ID: 11583303
[TBL] [Abstract][Full Text] [Related]
20. Carbon monoxide-releasing molecule-2 decreases fibrinolysis in human plasma.
Nielsen VG; Kirklin JK; George JF
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):448-55. PubMed ID: 19581800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
